Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and illegal practices that have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Hims engaged in deceptive practices, including the promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [4]. Group 2: Partnership Termination and Stock Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and deceptive marketing practices [5]. - Following the announcement, Hims' stock price plummeted by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant financial harm to investors [5]. Group 3: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct to support the investigation [7].

Core Viewpoint - A class action lawsuit has been filed against Reddit, Inc. for allegedly misleading investors regarding user growth and advertising revenue, particularly in light of changes to Google's search algorithm that negatively impacted Reddit's traffic [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Reddit securities between October 29, 2024, and May 20, 2025, with a deadline of August 18, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that Reddit made false statements and failed to disclose material information about the impact of Google's algorithm changes on user traffic [3]. Group 2: Allegations Against Reddit - Key allegations include that changes to Google Search's algorithm, such as the introduction of AI Overview, significantly reduced user click-throughs to Reddit [3]. - It is alleged that the increase in searches for "Reddit" did not indicate genuine user intent to visit the site, as users were finding answers directly on Google [3]. - The lawsuit asserts that these factors led to a significant drop in traffic that Reddit could not quickly offset, undermining its guidance on user growth and advertising revenue [3]. Group 3: Financial Impact - Following the release of Q1 2025 financial results on May 1, 2025, which showed a third consecutive quarter of slowing daily active user growth, Reddit's stock price declined [4]. - Analysts from Wells Fargo downgraded Reddit's stock on May 19, 2025, lowering the price target to $115 due to concerns over Google's AI features causing permanent disruption to user traffic [4]. - Baird analysts also downgraded Reddit's stock on May 21, 2025, cutting the price target to $120, citing ongoing U.S. user growth headwinds, which resulted in a stock decline of over 9% [5].

Core Viewpoint - Rocket Pharmaceuticals is facing a class action lawsuit due to allegations of misleading investors regarding the safety and protocol of its clinical trials for gene therapies [3][4]. Group 1: Company Overview - Rocket Pharmaceuticals is a late-stage biotechnology company focused on developing gene therapies for rare and serious diseases [2]. Group 2: Legal Allegations - The class action lawsuit claims that Rocket Pharmaceuticals provided updates on its Phase 2 trial of RP-A501 for Danon disease while making materially false statements and omitting critical adverse facts about the trial's safety [3]. - The lawsuit alleges that the company was aware of the risk of Serious Adverse Events (SAEs), including patient deaths, but did not fully inform investors [3]. - It is claimed that Rocket Pharmaceuticals amended the trial protocol to include a new immunomodulatory agent without disclosing this change to shareholders [3]. Group 3: Impact of FDA Action - On May 27, 2025, Rocket Pharmaceuticals announced that the U.S. FDA had placed a clinical hold on the RP-A501 Phase 2 trial following the death of a participant treated under the amended protocol, which had not been disclosed to investors [4]. - Following this announcement, Rocket Pharmaceuticals' stock price experienced a decline [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, primarily related to misleading statements and the promotion of illegitimate products, which led to a significant drop in stock price following the termination of a partnership with Novo Nordisk [1][2]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - Following the allegations, Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason [2]. - The lawsuit claims that the stock price of Hims & Hers fell by more than 34% after the announcement of the partnership termination [2]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [3]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [3]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [4]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [4].

Core Viewpoint - Vestis Corporation is facing a class action lawsuit due to allegations of providing misleading statements about its business growth and performance, leading to a significant drop in stock price following disappointing financial results [3][4]. Summary by Relevant Sections Allegations - The complaint against Vestis Corporation claims that the company made overwhelmingly positive statements while concealing material adverse facts about its business growth capabilities [3]. - Specifically, it is alleged that Vestis would be unable to execute planned strategic initiatives aimed at improving customer experience and driving new customer growth [3]. Financial Performance - On May 7, 2025, Vestis announced its second-quarter financial results for fiscal 2025, withdrawing its revenue and growth guidance for the full year [3]. - The company reported that its poor performance was due to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [3]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Class Action Details - Shareholders who purchased shares of Vestis during the class period from May 2, 2024, to May 6, 2025, are encouraged to register for the class action lawsuit [4]. - The deadline for shareholders to seek lead plaintiff status is August 8, 2025, and there is no cost or obligation to participate in the case [4]. Law Firm Information - The Gross Law Firm, which is handling the class action, is a nationally recognized firm dedicated to protecting investors' rights against deceit and fraud [5].

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=154297&fr ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=154294&from=3 CLASS PERIOD: Ju ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Companies, Inc. (NYSE: RKT). Shareholders who purchased shares of RKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rocket-companies-inc-loss-submission-form/?id=154293&from=3 CLASS PERIOD: March ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Red Cat Holdings, Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 18, 2022, to January 15, 2025 [3]. - Allegations include that the company overstated the production capacity of its Salt Lake City Facility and the value of the U.S. Army's Short Range Reconnaissance Program of Record Tranche 2 contract, leading to materially false and misleading public statements [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 22, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe ...